Agenus (AGEN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $6.68, +2.77% vs the prior close of $6.50.
- Volume 815.40K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AGEN rises 2.8% to $6.68. Closed at $6.68, +2.77% vs the prior close of $6.50. Day range $6.51–$6.99, opened at $6.52.
AGEN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — AGEN rises 2.8% to $6.68
- Closed at $6.68, +2.77% vs the prior close of $6.50. Day range $6.51–$6.99, opened at $6.52.
- Volume was 815.40K shares, 0.7x its 50-day average of 1.14M.
- Price is -13.8% vs its 50-day average ($7.75) and +39.9% vs its 200-day average ($4.78).
- 52-week range $2.71–$10.31; today's close sits at 52% of that range, 35.2% below the 52-week high.
Oct 14, 2026 — AGEN slides 6.5% to $6.50, a 1-month low, 3 down days in a row
- Closed at $6.50, -6.47% vs the prior close of $6.95. Day range $6.46–$7.14, opened at $6.88.
- Volume was 979.50K shares, 0.8x its 50-day average of 1.16M.
- Price is -16.4% vs its 50-day average ($7.77) and +36.6% vs its 200-day average ($4.76).
- 52-week range $2.71–$10.31; today's close sits at 50% of that range, 37.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — AGEN slides 6.5% to $6.95, a 1-month low
- Closed at $6.95, -6.46% vs the prior close of $7.43. Day range $6.81–$7.34, opened at $7.30.
- Volume was 991.80K shares, 0.8x its 50-day average of 1.17M.
- Price is -11.0% vs its 50-day average ($7.81) and +46.5% vs its 200-day average ($4.74).
- 52-week range $2.71–$10.31; today's close sits at 56% of that range, 32.6% below the 52-week high.
Oct 12, 2026 — AGEN slides 3.1% to $7.43
- Closed at $7.43, -3.13% vs the prior close of $7.67. Day range $7.39–$7.66, opened at $7.63.
- Volume was 572.50K shares, 0.5x its 50-day average of 1.19M — lighter than usual.
- Price is -5.1% vs its 50-day average ($7.83) and +57.3% vs its 200-day average ($4.72).
- 52-week range $2.71–$10.31; today's close sits at 62% of that range, 27.9% below the 52-week high.
Oct 9, 2026 — AGEN rises 1.7% to $7.67
- Closed at $7.67, +1.72% vs the prior close of $7.54. Day range $7.38–$7.79, opened at $7.50.
- Volume was 710.20K shares, 0.6x its 50-day average of 1.24M — lighter than usual.
- Price is -2.0% vs its 50-day average ($7.83) and +63.0% vs its 200-day average ($4.70).
- 52-week range $2.71–$10.31; today's close sits at 65% of that range, 25.6% below the 52-week high.
Oct 8, 2026 — AGEN dips 0.4% to $7.54
- Closed at $7.54, -0.40% vs the prior close of $7.57. Day range $7.24–$7.66, opened at $7.57.
- Volume was 1.21M shares, 1.0x its 50-day average of 1.25M.
- Price is -3.7% vs its 50-day average ($7.83) and +61.0% vs its 200-day average ($4.68).
- 52-week range $2.71–$10.31; today's close sits at 64% of that range, 26.9% below the 52-week high.
Oct 7, 2026 — AGEN rises 1.1% to $7.57
- Closed at $7.57, +1.07% vs the prior close of $7.49. Day range $7.27–$7.62, opened at $7.28.
- Volume was 1.16M shares, 0.9x its 50-day average of 1.29M.
- Price is -3.1% vs its 50-day average ($7.82) and +62.3% vs its 200-day average ($4.66).
- 52-week range $2.71–$10.31; today's close sits at 64% of that range, 26.6% below the 52-week high.
Oct 6, 2026 — AGEN slides 14.2% to $7.49
- Closed at $7.49, -14.20% vs the prior close of $8.73. Day range $7.47–$8.49, opened at $8.49.
- Volume was 1.52M shares, 1.2x its 50-day average of 1.28M.
- Price is -3.9% vs its 50-day average ($7.80) and +61.3% vs its 200-day average ($4.64).
- 52-week range $2.71–$10.31; today's close sits at 63% of that range, 27.4% below the 52-week high.
Oct 5, 2026 — AGEN jumps 4.4% to $8.73
- Closed at $8.73, +4.43% vs the prior close of $8.36. Day range $8.11–$8.76, opened at $8.54.
- Volume was 956.10K shares, 0.7x its 50-day average of 1.29M.
- Price is +12.4% vs its 50-day average ($7.77) and +88.8% vs its 200-day average ($4.62).
- 52-week range $2.71–$10.31; today's close sits at 79% of that range, 15.3% below the 52-week high.
Oct 2, 2026 — AGEN rises 0.4% to $8.36
- Closed at $8.36, +0.36% vs the prior close of $8.33. Day range $8.08–$8.61, opened at $8.36.
- Volume was 1.09M shares, 0.8x its 50-day average of 1.31M.
- Price is +8.4% vs its 50-day average ($7.71) and +81.8% vs its 200-day average ($4.60).
- 52-week range $2.71–$10.31; today's close sits at 74% of that range, 18.9% below the 52-week high.
AGEN latest news & SEC filings
Every SEC filing by or about AGEN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Harrison Thomas L received an award of 4,443 shares at $6.89 (≈$30.63K) on Oct 1, 2026; now holds 51,988
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 11, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 2, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
Aug 17, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $34.52M (prior year $25.69M) (+34.4% vs Jun 30, 2025)
- Diluted EPS: -$0.01 (prior year -$1.00) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade AGEN
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 16, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.86% (largest 16.1%). That is a volatile stock.
- Liquidity: about 1.19M shares (≈$7.98M) trade per day on average.
- 52-week position: $6.68 vs a range of $2.71–$10.31 (52% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 18, 2026; 8-K Aug 13, 2026; 8-K Aug 11, 2026.
- Share count: 45.02M shares outstanding (Aug 4, 2026), +41.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
AGEN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 6.52 | 6.99 | 6.51 | 6.68 | 815.40K |
| Oct 14, 2026 | 6.88 | 7.14 | 6.46 | 6.50 | 979.50K |
| Oct 13, 2026 | 7.30 | 7.34 | 6.81 | 6.95 | 991.80K |
| Oct 12, 2026 | 7.63 | 7.66 | 7.39 | 7.43 | 572.50K |
| Oct 9, 2026 | 7.50 | 7.79 | 7.38 | 7.67 | 710.20K |
| Oct 8, 2026 | 7.57 | 7.66 | 7.24 | 7.54 | 1.21M |
| Oct 7, 2026 | 7.28 | 7.62 | 7.27 | 7.57 | 1.16M |
| Oct 6, 2026 | 8.49 | 8.49 | 7.47 | 7.49 | 1.52M |
| Oct 5, 2026 | 8.54 | 8.76 | 8.11 | 8.73 | 956.10K |
| Oct 2, 2026 | 8.36 | 8.61 | 8.08 | 8.36 | 1.09M |
| Oct 1, 2026 | 9.95 | 9.99 | 8.28 | 8.33 | 1.95M |
| Sep 30, 2026 | 9.92 | 10.31 | 9.62 | 9.93 | 1.37M |
| Sep 29, 2026 | 9.66 | 10.06 | 9.43 | 9.89 | 1.50M |
| Sep 28, 2026 | 8.71 | 9.71 | 8.47 | 9.43 | 2.76M |
| Sep 25, 2026 | 8.57 | 8.68 | 8.40 | 8.54 | 672.40K |
| Sep 24, 2026 | 8.32 | 8.60 | 8.20 | 8.50 | 635.70K |
| Sep 23, 2026 | 8.70 | 8.70 | 8.39 | 8.40 | 610.00K |
| Sep 22, 2026 | 8.26 | 8.82 | 8.16 | 8.70 | 993.30K |
| Sep 21, 2026 | 7.80 | 8.60 | 7.60 | 8.33 | 1.30M |
| Sep 18, 2026 | 7.48 | 7.88 | 7.33 | 7.85 | 2.08M |
About Agenus
Agenus (AGEN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in LEXINGTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1098972.
AGEN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Garo H Armen | See Remarks | Aug 12, 2026 |
| Jennifer Buell | See Remarks | Aug 7, 2026 |
| Brian Corvese | Director | Aug 11, 2026 |
| Thomas L Harrison | Director | Aug 11, 2026 |
| Susan B Hirsch | Director | Aug 7, 2026 |
| Marco Tullio Marcucci | Director | Sep 16, 2026 |
| Timothy Wright | Director | Aug 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Garo H Armen | See Remarks | Aug 12, 2026 |
| Jennifer Buell | See Remarks | Aug 7, 2026 |
| Austin Charette | Principal Accounting Officer | Apr 28, 2026 |
| Steven J O'Day | Chief Medical Officer | Aug 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
AGEN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $114.20M | — | 0.00 | $-77.19M |
| Dec 31, 2024 | $103.46M | — | -10.59 | $-158.31M |
| Dec 31, 2023 | $156.31M | — | -13.75 | $-224.20M |
| Dec 31, 2022 | $98.02M | — | -15.64 | $-175.37M |
| Dec 31, 2021 | $295.67M | — | -0.11 | $10.14M |
Latest balance sheet: total assets $172.69M, total liabilities $—, cash $18.74M (as of Jun 30, 2026).
AGEN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $7.49 |
| May 11, 2026 | 8-K Item 2.02 (results) | $3.26 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $3.29 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $4.21 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $4.27 |
| May 12, 2025 | 8-K Item 2.02 (results) | $3.50 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $2.05 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $3.11 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on AGEN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.